The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | M | Musculo-skeletal system | |
| 2 | M03 | Muscle relaxants | |
| 3 | M03B | Muscle relaxants, centrally acting agents | |
| 4 | M03BX | Other centrally acting agents | |
| 5 | M03BX01 | Baclofen |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 50 mg |
| PAREN - Parenteral | 0.55 mg |
| Active Ingredient | Description | |
|---|---|---|
| Baclofen |
Baclofen depresses monosynaptic and polysynaptic reflex transmission, probably by stimulating the GABAB-receptors. This stimulation in turn inhibits the release of the excitatory amino acids glutamate and aspartate. Neuromuscular transmission is unaffected by baclofen. Baclofen also exerts an antinociceptive effect. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| COLMIFEN Tablet | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
| GABLOFEN Solution for injection | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| LIORESAL Solution for intrathecal injection / infusion | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
